Project Grant R43AI170237
Award Date
9/1/22
Completion Date
4/30/23
Dollars Obligated
$432K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Lawrence, KS 66047, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $216,759 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona for the development of a transdermal nanoemulsion-based gel formulation containing the antiretroviral drugs dolutegravir and rilpivirine. The goal is to create a non-invasive, room temperature stable treatment option for long-term management of HIV infection in pediatric patients. The project...
This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $2,207,322 to the University of Nebraska Medical Center (UNMC) for developing ultra-long-acting antiretroviral therapy (ART) formulations for HIV-1 treatment in pediatric populations. The key objective is to create a complete 6-month injectable ART regimen using integrase strand transfer inhibitors (INSTIs) like bictegravir and...
This $807,257 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance the development of a microneedle patch technology for delivering broadly neutralizing antibodies (BnAbs) to prevent HIV-1 transmission to infants through breastfeeding. The 5-year project, awarded to Old Dominion University (ODU) with involvement from the ODU Research Foundation, will rigorously...
This $1,314,701 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to optimize dolutegravir-based antiretroviral therapy (ART) for children and adolescents. The project will be led by the University of Florida and will involve collaborations with researchers at Kwame Nkrumah University of Science and Technology (KNUST) in Ghana and the University of Rochester....
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to demonstrate the feasibility of a 3D-printed, dose-flexible pediatric delivery system for the treatment of pediatric toxoplasmosis. The $581,052 award, with an initial period of performance from September 2024 to May 2029, will support the development, assessment, and characterization of a 3D-printed...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $208,575 to the University of Arizona to develop, characterize, and evaluate an ionic liquid-based nanoemulsion containing a combination of antiretroviral drugs (dolutegravir and rilpivirine) for oral and transdermal delivery to treat HIV infection. The primary objectives are to improve the oral bioavailability...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $431,712 to The Regents of the University of California, San Francisco (UCSF) to implement and evaluate an innovative HIV testing program for children aged 18 months to 5 years in rural Uganda. The key objectives are: Determine barriers and facilitators to pediatric HIV testing, and adapt a traditional healer-facilitated HIV testing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $448,765 to Oregon Health & Science University (OHSU) to conduct research on the persistence of HIV-specific CD8+ T cell responses in early-treated Thai children. The primary objectives are to: (1) determine the magnitude, phenotype, and functionality of HIV-specific CD8+ T cells that persist in early-treated...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,595 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University to develop a self-administered microneedle patch for the long-acting release of antiretroviral agents. The key objectives are to: 1) formulate and optimize the extended release of an antiretroviral agent (islatravir/EFDA) from biodegradable microneedle patches for at least one month, and 2) evaluate the...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $170,639 to the University of North Carolina at Chapel Hill to characterize adherence and estimate per-protocol effects for pediatric dolutegravir use. The key objectives are to (1) characterize the barriers to pediatric dolutegravir combination therapy adherence, and (2) estimate...